



**Advisory Committee to the Director
Centers for Disease Control and Prevention (CDC)
Sheraton Atlanta Hotel
Atlanta, Georgia**

January 18, 2001

MEETING MINUTES



**Department of Health and Human Services
Public Health Service**

Advisory Committee to the Director, CDC

The Advisory Committee to the Director, CDC, convened January 18, 2001, in Capital Ballroom South of the Sheraton Atlanta Hotel, Atlanta, Georgia. Presiding was Charles S. Mahan, M.D., Chair of the Committee and Kathy Cahill, Associate Director for Program, Planning and Evaluation, CDC, served as the Executive Secretary. Members from the Advisory Committee to the Director, CDC, Chairpersons from other CDC advisory committees, boards of scientific counselors, and CDC's Agency for Toxic Substances and Disease Registry(ATSDR) served as consultants to the Committee.

Committee Members Present:

Stephanie B.C. Bailey, M.D., M.S.H.S.A., Director for Health, Metropolitan Health Department; Nashville, Tennessee
Diana M. Bonta, R.N., Dr.P.H., Director, California Department of Health Services; Sacramento, California
Helene G. Brown, Associate Director, Community Research, Jonsson Comprehensive Cancer Center, UCLA; Los Angeles, California
Daniel Callahan, Ph.D., Director of International Programs, The Hastings Center; Garrison, New York
Gail H. Cassell, Ph.D., Vice President, Infectious Diseases Drug Discovery Research and Clinical Investigation, Eli Lilly & Company; Indianapolis, Indiana
Barbara DeBuono, M.D., M.P.H., Medical Director, Public Health, Pfizer Pharmaceutical Group, Pfizer, Inc.; New York, New York
Ruth J. Katz, J.D., M.P.H., Associate Dean for Administration, Yale School of Medicine; New Haven, Connecticut
William L. Roper, M.D., M.P.H., Dean, School of Public Health, University of North Carolina at Chapel Hill; Chapel Hill, North Carolina
Edgar F. Thompson, Jr., M.D., M.P.H., State Health Officer, Mississippi Department of Health; Jackson, Mississippi
Eugene Washington, M.S., M.Sc., Professor and Chair, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco; San Francisco, California

Committee Members Absent:

George A.O. Aleyne, M.D., Director, Pan American Health Organization; Washington, DC
Michael M.E. Johns, M.D., Executive Vice President for Health Affairs, Emory University; Atlanta, Georgia

Chairpersons Representing other CDC and ATSDR Advisory Committees and Boards of Scientific Counselors:

Thomas A. Burke, Ph.D., Advisory Committee to the Director, National Center for Environmental Health, Associate Professor of Health Policy Management, Johns Hopkins University; Baltimore, Maryland
Enriqueta C. Bond, Ph.D., Board of Scientific Counselors, National Center for Infectious Diseases, President, The Burroughs Wellcome Fund; Research Triangle Park, North Carolina
James A. Merchant, M.D., Dr.P.H., Board of Scientific Counselors, National Institute for Occupational Safety and Health, Professor and Dean, The University of Iowa College of Public Health; Iowa City, Iowa

CDC Participants:

Jeffrey P. Koplan, M.D., M.P.H., Director, Centers for Disease Control and Prevention; Atlanta, Georgia

Martha Katz, M.P.A., Deputy Director for Policy and Legislation, Centers for Disease Control and Prevention; Atlanta, Georgia

Virginia S. Bales, M.P.H., Deputy Director for Program Management, Centers for Disease Control and Prevention; Atlanta, Georgia

Kathy Cahill, M.P.H., Executive Secretary and Associate Director for Program, Planning and Evaluation, Centers for Disease Control and Prevention; Atlanta, Georgia

Pamela G. Joseph, Program Specialist, Office of Program Planning and Evaluation, Centers for Disease Control and Prevention; Atlanta, Georgia

Summary

Opening Remarks: Charles Mahan, MD, Chair

Dr. Mahan welcomed the committee to the first Advisory Committee meeting for the year 2001.

Welcome and Announcements: Jeffrey Koplan, MD, MPH

Dr. Koplan welcomed the Advisory Committee and introduced the scientific presentations.

Biographies for the speakers were included in the notebook handed out to all present at the meeting.

CDC Scientific Presentations and Discussions

Ebola and Rift Valley Fever Outbreaks: James LeDuc, PhD

Dr. LeDuc presented information on Rift Valley fever, including background information on the disease, impact of the disease, and geographic distribution in Saudi Arabia. Transmission is by infected mosquitoes to susceptible humans or by exposure to aerosolized blood from infected animals. A team was in Saudi Arabia September - November 2000.

Dr. LeDuc then provided an update on the current Ebola outbreak and its geographic spread in Uganda. He provided a brief history of Ebola. There continues to be a fair number of nosocomial infections with this disease. These infections are being investigated and may be related to health care workers not wearing protective equipment. It is likely that the outbreak is nearing an end. The CDC has sent 21 people to the field in response to these outbreaks. Investigators will remain on site through February to be certain that the outbreak has ended.

Dr. LeDuc then answered questions from the committee about these two outbreaks. The committee asked about CJD outbreaks in the U.S. and in Europe. The committee also asked about infrastructure & numbers of staff available to respond to outbreaks and numbers who remain at headquarters to staff offices. Program had budgeted \$750,000 for response to outbreaks for FY 2001.

First National Exposure Report Card: Eric Sampson, PhD:

Dr. Sampson provided background information on the first National Report on Human Exposure to Environmental Chemicals. A one-page summary was provided in Section 4 of the meeting notebook. Dr. Sampson covered the material on the handout.

CDC is at the forefront of measuring toxicants in humans. CDC has the ability to measure 250 toxicants in humans. Current tests are very sensitive & they are able to measure very low levels of toxicants.

Data from the NHANES survey is used to collect samples which are used to measure toxicants. This year 50 different substances will be measured; measurement of 25 new substances will be added each year.

The report card will tell us which toxicants Americans are exposed to, who is exposed, the level of exposure, and trends in exposure. This information will also identify which toxic substances might be candidates for future research.

The data will be published in multiple forms, and available on the Internet.

Dr. Jackson, Director, NCEH provided a few comments on the importance of this research.

CDC staff responded to questions from the committee.

CDC Updates: Jeffrey Koplan:

Dr. Koplan provided an update on the Children's Health Act and the designation of the new National Center of Birth Defects and Developmental Disabilities at CDC.

Dr. Koplan then provided information on staffing changes: Dr. Sue Binder as Director, National Center for Injury Prevention and Control; Dr. Larry Fine as Acting Director, National Institute of Occupational Safety and Health; and Dr. Rita Gregory as Director of Facilities Management.

Dr. Koplan also invited the committee to provide feedback on the name of the TMNational Exposure Report Cards and to provide suggestions for changing the descriptor from TMReport cards to a better descriptor. (Report has been renamed the National Report on Human Exposure to Environmental Chemicals).

Committee Reports:**Prevention Research Report: William Roper, MD, MPH:**

Dr. Roper provided a report from the Prevention Research workgroup of the Advisory Committee. The report covered the current status of prevention research at CDC and the challenges for the future which includes mobilizing stakeholders through advocacy and dissemination and translation of research findings into action.

A Harris poll has shown that support for prevention research is high; however, awareness of CDC's role in prevention research is low. Therefore, critical success factors include the articulation of the unique niche for CDC and demonstration of the impact of research.

CDC and PHPPPO are currently searching for a Director of the new Office of Extramural Prevention Research. Copies of Dr. Roper's slides were handed out at the meeting.

Dr. Roper responded to questions and comments from the committee.

Aging Workgroup: Helene Brown:

Ms. Brown provided a report from the Aging Workgroup. Key points from the workgroup meeting of January 17, 2001:

- α CDC can play a major role in the healthy aging arena in the nation
- α TMHealthy aging lacks a national leader; there are many players, but no real leadership organization
- α There are no TMnatural enemies α i.e., no one is against supporting healthy aging effort
- α Thousands of potential partners
- α CDC must bring resources to be taken seriously; CDC should seek out funding
- α This is a great opportunity with the new administration.

A vision must be set; we must determine the outcomes and what needs to be done to achieve those outcomes, and we need to create the agenda, with CDC as the leader/convener.

The readily available objectives include: utilizing proven, cost-effective interventions (physical activity, improving diet, lowering obesity, smoking cessation, clinical preventive services); the Aging Network's health promotion mandate; translation of NIA-sponsored research.

It will be important to raise awareness of the issues and CDC's role; align awareness activities with the CDC Identity Project, use CDC's data capabilities to highlight the issues; build a constituency for "Healthy Aging"; engage philanthropies and the private sector; think of this as a long-term effort. Additional information was provided in the notebook. This group will meet again in the near future to develop a vision and agenda to guide CDC in this area. A brief discussion along with a question and answer period followed this report.

Ethics Subcommittee: Daniel Callahan, PhD:

Dr. Callahan provided a report from the Ethics Subcommittee. The subcommittee provided recommendations on ethical issues related to the protocol of a study on transmission of Human Herpesvirus 8 (HHV8) through exposure of blood to infected individuals. This research was observational in nature.

CDC Updates:

New Legislation: Martha Katz, MPA:

Martha Katz provided an update on recent authorizing legislation affecting CDC. Several bills passed by the last Congress contained language that affect CDC programs. Ms. Katz provided an overview of four of these laws: The Public Health Improvement Act of 2000; the Children's Health Act of 2000, which mandated the creation of a new Center at CDC along with several other provisions; the Radiation Compensation Act; and the Breast and Cervical Cancer Treatment Act of 2000. Additional information was provided in Tab 5 of the notebook.

This presentation was followed by discussion and questions and answers.

FY 2001 Budget: Virginia S. Bales, MPH:

Virginia Bales provided an update on the Building and Facilities Masterplan, Financial Management Excellence, and the Fiscal Year 2001 budget. Additional information on CDC's FY 2001 appropriation was provided in Tab 6 of the notebook.

This presentation was followed by discussion and question and answers.

The Committee broke for lunch:

CDC Scientific Presentation:

LIFE Initiative: Dr. Eugene McCray, MD:

Dr. McCray gave a presentation on the Leadership and Investment in Fighting an Epidemic (LIFE) initiative, accompanied by a handout of the presentation. The presentation included a brief history of LIFE, details on the LIFE initiative including guiding principles, objectives, and accomplishments, and future plans for the initiative.

The presentation was followed by discussion and question and answers.

Director's Priorities for 2001: Jeffrey Koplan, MD, MPH:

Dr. Koplan listed the top priorities for 2001, clarifying that they are not ranked in any particular order:

- > Building Public Health Infrastructure
- > National security issues, such as bioterrorism, emerging infections, environmental threats.
- > Increased focus on chronic diseases, including prevention research
- > Global Health

- › Buildings and Facilities
- › Internal Workforce Plan
- › Financial Management Initiative
- › Elimination of Health Disparities
- › A common CDC identity
- › Transition with the new Administration

Recommendations from the Board for Future Presentations:

- › A presentation on increased funds and responsibility in fiscal management to ASTHO and NACCHO should be considered.
- › A report on CDC and the management of resources would be welcomed.
- › A presentation on Global Health should be a part of the next meeting.

The meeting was adjourned by Dr. Koplan, with closing remarks by Dr. Mahan.

Certification Page

I certify that the foregoing summary of the meeting is accurate and complete to the best of my knowledge.

Charles S. Mahan, M.D., Chairman

Kathy Cahill, M.P.H.
Executive Secretariat, ACD, CDC